baber/WOPTO huggingface dataset:
Patent CA-2277260-A1 (CA)
Inventor: ST-PIERRE YVES
IPC: G05G5/08
Filed: 1999-07-09
Abstract: The assembly (10) is for use with a mecnanical leverage system (24) mounted on a frame (14), for instance the frame of a vehicle (12), to move an implement (16) between a lowered position and a lifted position. The assembly (10) comprises an elongated first lever arm (30) and a second lever arm (40) that is in motion-transmitting engagement with a lower end (32) of the first lever arm (30). A detent member (50) is provided to lock the second lever arm (40) in an intermediary position located between a first and a second limit position thereof. The intermediary position corresponds to the lifted position of the implement (16). The detent member (50) is released by further pivoting the first lever arm (30) so as to move the second lever arm (40) from its intermediary position to its second limit position. The detent member (50) is then released without having to independently operate a locking mechanism or to move the first lever arm (30) sidewards.
Patent CA-2278485-A1 (CA)
Inventor: IIJIMA MASAHIKO
IPC: C10G49/04
Filed: 1998-11-17
Abstract: A hydrotreating catalyst composed essentially of a carrier having a Brønsted acid content of 50.mu. mol/g or above, e.g., one comprising silica, alumina and, if necessary, other components in which the silica is highly dispersed and which has a Brønsted acid content of 50.mu. mol/g or above, and at least one active component selected from among group 8 elements of the periodic table and at least one active component selected from among group 6 elements thereof which are supported on the carrier; and processes for hydrotreating hydrocarbon oil with the catalyst. The catalyst exhibits an excellent resistance to inhibition by hydrogen sulfide and a high desulfurization activity and can exert remarkable effects in the depth desulfurization of hydrocarbon oil having a high sulfur content, particularly a gas oil cut containing difficultly desulfurizable sulfur compounds. Further, the catalyst is extremely effective also in the hydrodenitrogenation, hydrocracking, hydrodearomatization, hydroisomerization and hydrorefining of hydrocarbon oil, and so on.
Patent CA-2278603-A1 (CA)
Title: Process for the production of semi synthetic statins via novel intermediates
Inventor: VRIES TON RENE
IPC: C07D309/30
Filed: 1998-01-27
Abstract: A process has been provided to produce semi synthetic statins, as for instance simvastatin with a high yield, from another statin, preferably a naturally occurring statin, as for instance lovastatin. Also a number of novel intermediate compounds, prepared during said process, has been provided.
Patent CA-2278607-A1 (CA)
Inventor: LEUTERT RUDI
IPC: F16B2/06
Filed: 1998-11-02
Abstract: The invention relates to a clamping device for elongated bodies (4) comprising a tubular sleeve (1) having a cap (2) with a cylindrical hole (3) for receiving said body, at each of its ends. The sleeve surrounds an elongated and toroidal pressure body (6) filled with a liquid or gaseous pressure medium and submitted to a pressure. The pressure body (6) comprises, for example, two concentric flexible tubes (5) having their ends connected to one another, and is connected to the pressure medium control system by means of a valve (7). When the pressure body (6) is submitted to a pressure, its walls are compressed both outwardly against the sleeve (1) and inwardly against the elongated body (4). The clamping action is thus applied uniformly on the whole surface of the body (4) located within the sleeve (1).
Patent CA-2278640-A1 (CA)
Title: Bistable spring construction for a stent and other medical apparatus
Inventor: BESSELINK PETRUS ANTONIUS
IPC: A61F2/06
Filed: 1998-01-23
Abstract: The present invention is directed to bistable cells and their use in devices, particularly medical devices such as stents, clamps and valves. An expandable stent formed of a plurality of bistable cells is described. The stent has two or more sta-ble configurations, including a first stable configuration with a first diameter and a second stable configuration with a second, larger diameter. A valve comprising a bistable cell for use in eliminating inconti-nence is also disclosed.
Patent CA-2279559-A1 (CA)
Inventor: CHARRIERE PATRICK
IPC: H04B7/26
Filed: 1999-08-03
Abstract: The invention relates to a method of changing the encoding level of digital data transmitted between a transmitter and a receiver at a constant rate, said encoding level being determined as a function of the quality of the signal received by said receiver, an encoding level of rank 0 being defined as providing the highest degree of protection for said transmitted data and an encoding level of rank n-1 as providing a lowest degree of protection to said transmitted data. According to the invention, the method consists, during a fixed time of non-zero length, in preventing a changeover from an encoding level of rank n, where 0 ~ m < n-1, to an encoding level of rank m+q, where 0 < m+q ~ n-1, and where q is positive, after said received signal quality corresponds to encoding at the level m+q.
Patent CA-2279900-A1 (CA)
Inventor: DE WAEGENEER PIERRE A
IPC: C08L23/10
Filed: 1998-02-24
Abstract: This invention relates to a film comprising a first surface layer comprising a homopolymer of ethylene having an Mw/Mn of 3 or less or a copolymer of ethylene and up to 50 weight % of a C3 to C20 olefin having a CDBI of 50 % or more wherein the first surface layer is sealed to a substrate, preferably comprising a homopolymer of propylene or copolymer of propylene and up to 50 weight % of a comonomer.
Patent CA-2280725-A1 (CA)
Title: Method for generating a group of page files formatted in a page markup language
Inventor: CRUSIUS FRIEDBERT
IPC: G06F17/30
Filed: 1998-02-11
Abstract: When drawing up a hierarchically structured document in an author file AT, a reference to a data record of a file already stored in the authoring system can be generated. The author file is sub-classified into individual data records which are respectively stored as pages on an Internet server. The added reference is converted into an HTML page address.
Patent CA-2281191-A1 (CA)
Title: Discharge lamp and lighting system having a discharge lamp
Inventor: REINERS THOMAS
IPC: F21W107/10
Filed: 1999-08-26
Abstract: The invention relates to a discharge lamp whose discharge vessel (1) is provided with a light-transmitting, electrically conductive layer (4) in order to improve the electromagnetic compatibility of the lamp when it is operated from an electronic operating unit. The light-transmitting, electrically conductive layer (4) is advantageously connected to the circuitry-internal ground potential of the operating unit.
Patent CA-2281620-A1 (CA)
Title: Recepteur de la neurturine
Inventor: KLEIN ROBERT D
IPC: C12N15/09
Filed: 1998-02-17
Abstract: L'invention concerne le récepteur de la neurturine .alpha. (NTNR.alpha.), le domaine extracellulaire (ECD) du NTNR.alpha., des variants du NTNR.alpha., un NTNR.alpha. chimère (tel qu'une immuno-adhésine du NTNR.alpha.) et des anticorps qui se fixent sur le NTNR.alpha. (notamment des anticorps agonistes et neutralisants). Elle concerne également diverses utilisations de ces molécules, notamment des méthodes permettant de moduler l'activité et la survie des cellules par une réponse aux ligands du NTNR.alpha., par exemple la neurturine, en fournissant à la cellule des NTNR.alpha..
Patent CA-2281794-A1 (CA)
Title: Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
Inventor: SHAHROKH ZAHRA
IPC: A61K47/48
Filed: 1998-02-20
Abstract: Humanized anti-IL-8 monoclonal antibodies and variants thereof are described for use in diagnostic applications and in the treatment of inflammatory disorders. Also described is a conjugate formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugate exhibits substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment.
Patent CA-2281873-A1 (CA)
Inventor: LANGENSIEPEN HANS-WERNER
IPC: C07C209/78
Filed: 1998-02-20
Abstract: Selon ce procédé de préparation de mélanges de polyamines aromatiques qui contiennent des composés de formule générale (I) H¿2?N-A-CH¿2?-B-NH¿2? dans laquelle A et B désignent des radicaux 1,4-phénylènes qui peuvent comprendre indépendamment les uns des autres 1 à 4 substituants sélectionnés parmi les radicaux alkyles-C¿1-20? et les atomes d'halogènes, on fait réagir un composé de formule générale (IV) H-A-NH-CH¿2?-HN-B-H et/ou un composé de formule générale (V) H-A-NH-CH¿2?-B-NH¿2?, dans laquelle A et B sont substitués comme décrit ci-dessus, à une température comprise entre 20 ·C et 200 ·C en présence d'un catalyseur constitué d'un ou de plusieurs oxydes d'éléments des 3e à 10e groupes de la table périodique des éléments, ce catalyseur pouvant être activé par un acide.
Patent CA-2282548-A1 (CA)
Title: Systeme d'application de radiations gonflables puis degonflables en vue de son retrait
Inventor: HASTINGS ROGER N
IPC: A61M25/00
Filed: 1998-01-08
Abstract: Cette invention se rapporte à un dispositif et à un procédé pour iradier les parois intérieures de vaisseaux du corps humain. Dans une réalisation un tel dispositif (21) comprend un tube en métal segmenté émettant des radiations bêta, disposé à l'extrémité distale d'un bras allongé (38). Dans une autre réalisation, un tel dispositif (121) comprend un manchon élastique radioactif (140) monté sur un bras (138). Le dispositif (121) peut servir à empêcher les resténoses à la suite d'une angioplastie des artères coronaires. Lors de l'utilisation, ledit dispositif (121) peut être avancé en position distale sur la partie ballonet (44) d'un cathéter à ballonnet d'angioplastie (20) mis en place et à l'état dégonflé, puis le ballonnet (44) est gonflé, vanant ainsi pousser le dispositif d'application des radiations en contact étroit avec les parois du vaisseau. Après une période d'exposition désirée, le ballonnet (44) est dégonflé et le dispositif (21) amené de force à se contracter, se contracte avec le ballonnet (44), pour qu'on puisse facilement le retirer du corps du patient.
Patent CA-2284129-A1 (CA)
Inventor: HUGHES JOHN V
IPC: H04B1/10
Filed: 1998-03-12
Abstract: These and other objects of the present invention are achieved using an Adaptive Multi-Path Filter (AMPF) which eliminates audibly objectionable click noise generated at the output of an FM discriminator to prevent audible distortion or other corruption of the desired signal which may include voice and low speed digital data. Clicks are detected at the discriminator output using a colored-noise, matched filter designed and adapted to the click signature/shape as well as to the desired signal characteristics. The colorednoise matched, filter output is then compared to an adaptive threshold. When the threshold is exceeded, a click is registered as detected. Click duration is then estimated. An estimate of the desired signal is generated and that replaces the originally received data signal estimate within the click duration region. Using characteristics of the desired signal just before and after the detected click noise, the adaptive filter accurately estimates the parameters of the desired signal so that the replacement signal fairly models what the desired signal would have looked like had the click not occurred. In this way, a substantial portion of the desired signal is preserved.
Patent CA-2284398-A1 (CA)
Inventor: HASPESLAGH JOHAN JOSEPH GUSTAA
IPC: H04L69/40
Filed: 1999-09-29
Abstract: A method is described to compensate for distortions in a communications network wherein a central station is coupled to a plurality of user network terminals via a plurality of communication channels consisting of the cascade connection of a plurality of user network terminal links and a common link. By this method, distortions which are common to all of said communication channels are equalised within said central station, whereas distortions which are only dependent on one respective communication channel, are compensated within the respective user network terminal coupled to this respective communication channel, by performing within said respective user network terminal, a pre-correcting step on signals to be transmitted by said respective user network terminal. A user network terminal, central station and a communications network adapted to perform the present method are also described.
Patent CA-2285626-A1 (CA)
Inventor: KAUFMAN JEFFREY R
IPC: G06K7/12
Filed: 1998-04-08
Abstract: Cette invention se rapporte à un symbole de code à barres couleur (8), qui peut être décodé avec précision malgré les distorsions importantes, les erreurs de lecture et les altérations. Ce code à barres (8) est constitué par un code à barres à transition des couleurs (8) ayant des propriétés de croissance linéaire conçues pour offrir une résistance aux effets simples ou combinés des distorsions par mise à l'échelle, des distorsions de perspectives, des distorsions par cisaillement et des distorsions par ondulation à la fois du type uniforme et du type non uniforme, le long de l'axe vertical (12) ou horizontal (10) du code à barres. Ce code à barres (8) résiste également aux symboles manquants et aux symboles altérés, tout en offrant un degré de sécurité élevé, des capacités de contrôle des erreurs et des capacités de correction des erreurs doubles.
Patent CA-2287590-A1 (CA)
Title: Novel molecules of the fthma-070-related protein family and the t85-related protein family and uses thereof
Inventor: MCCARTHY SEAN A
IPC: G01N33/53
Filed: 1998-04-17
Abstract: Blank page
Patent CA-2290537-A1 (CA)
Title: Use of taurolidine for treatment of leukemias
Inventor: MORRISSEY JAMES H
IPC: A61K31/549
Filed: 1998-05-22
Abstract: Taurolidine (taurolin; tauroline; 4,4'-methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide) has been found to be an effective agent for treating patients inflicted with monocytic and/or myeloid leukemias through the induction of apoptosis in leukemia cells. Concentrations of taurolidine in the range of 50 to 100 µg/ml induced apoptosis in 75 % of peripheral blood monocytes incubated in culture medium within six hours. Further, 100 µg/ml taurolidine induced apoptosis in 92 %  of granulocytes incubated in culture medium within six hours.  Taurolidine was also effective in reducing the hypercoagulable state associated with tissue factor expression on leukemia cells, providing a means by which the incidence and degree of severity of coagulopathies associated with tissue factor expression can be reduced in leukemia patients. Preferred therapeutic dosages for treatment of leukemias are from about 10 to about 500 mg/kg body weight. Most preferred is a dose that results in a 200 µg/ml concentration in the plasma, which is typically about 150 mg/kg body weight.
Patent CA-2290614-A1 (CA)
Inventor: DOEMLING ALEXANDER
IPC: C07H21/00
Filed: 1998-05-14
Abstract: Dans la présente invention, on divulgue une méthode pour produire des polymères présentant des nucléobases comme groupes latéraux, au moyen de réactions avec plusieurs composants, en particulier au moyen d'une réaction de Ugi. Etant donné que cette production est fondée sur l'utilisation de plusieurs composants, on peut faire varier plus qu'avant les propriétés des polymères et les adapter afin de satisfaire aux exigences d'utilisation comme agent thérapeutique antisens ou antigénique ou comme réactif de diagnostic.
Patent CA-2291873-A1 (CA)
Inventor: CRUZ MERCEDES MENDOZA
IPC: C11D17/00
Filed: 1999-12-01
Abstract: The present invention relates to active chlorine preparations containing optical brighteners which are distinguished by the fact that the optical brighteners are present in microencapsulated form.
Patent CA-2295920-A1 (CA)
Title: Oligonucleotide reverse transcription primers for efficient detection of hiv-1 and hiv-2 and methods of use thereof
Inventor: PATTERSON DAVID R
IPC: G01N33/53
Filed: 2000-02-01
Abstract: Disclosed herein are methods and kits for the detection of human immunodeficiency virus in biological samples from human subjects.      Oligonucleotide reverse transcription primers for use in such methods and kits for detection of human immunodeficiency virus are also described.
Patent CA-2296044-A1 (CA)
Title: Oligonucleotide primers for efficient multiplex detection of hepatitis c virus (hcv) and human immunodeficiency virus (hiv) and methods of use thereof
Inventor: GORMAN KEVIN M
IPC: G01N33/569
Filed: 2000-02-01
Abstract: Disclosed herein are methods and kits for the simultaneous detection of hepatitis C virus and human immunodeficiency virus in biological samples from human subjects.
Patent CA-2297878-A1 (CA)
Inventor: JOHNSTON DAVID
IPC: G11C7/10
Filed: 2000-02-03
Abstract: A synchronous single port random access memory comprises a core 2 of memory cells 3 arranged as rows and columns. The rows are addressed by a row decoder 5 and the memory cell outputs are connected as columns to a column decoder and multiplexer 7. The decoder and multiplexes 7 selects groups of memory cells 3 from the addressed row and connects these to sense amplifiers 8. Changes in address are propagated immediately to the core 2 so that the selected memory cells 3 are connected as quickly as possible and without any fixed delays to the sense amplifiers 8. Similarly, a read clock "rclk" enables the sense amplifiers 8 immediately upon becoming active.
Patent CA-2299364-A1 (CA)
Inventor: KUHN WALTER
IPC: C07D307/62
Filed: 1998-07-24
Abstract: L'invention concerne un procédé de préparation d'acide L-ascorbique par réaction d'acide 2-cétone-L-gulonique avec de l'acide minéral concentré à des températures comprises entre 40 et 80 ·C.
Patent CA-2300444-A1 (CA)
Inventor: DETORO JOHN EDWARD
IPC: B65D83/08
Filed: 2000-02-28
Abstract: Existing tissue boxes with a slotted cellophane opening or narrow rectangular opening, do not permit easy or convenient 100% retrieval of the last few remaining tissues. Most tissue boxes have an interwoven pop up design. As a tissue is extracted it pulls up the next tissue for easy retrieval. It is a common fact this system does not function efficiently to enable retrieval of the last few remaining tissues. Most specifically when the tissues in the box or container reach the approximate amount of 15% to 20% or less remaining in the container.  In many cases the consumer may in frustration at being unable to extract remaining tissues, discard the box with the remaining tissues. This undoubtably results in unnecessary waste and cost to the consumer. I have found this inconvenience can be overcome by adding an accordion style folds/ pleated paperboard spring system installed in the bottom of the tissue box, compressed between the tissues and the floor of the tissue box such as in Kleenex, Scotties or No Name The objective of the spring system is to permit retrieval of the last remaining tissues without having to dig deep into the box to retrieve the tissues. As the tissues become less and less the folds expand upward, pushing against the tissues and keeping them tight to the retrieval opening permitting the last tissue to be extracted. It is my opinion that the manufacturing of the folds in mass quantities and the cost involved to adding this system, would be offset in the extra sales and choice by consumers for this extra convenience.
Patent CA-2302486-A1 (CA)
Inventor: STOREY ALAN
IPC: C12Q1/68
Filed: 1998-08-31
Abstract: The present invention relates to a screening method to identify individuals at risk of developing diseases associated with different polymorphic forms of wildtype p53; which comprises the steps of: a) obtaining a biological sample from said patients; and b) determining the presence of p53pro or p53arg wildtype alleles in said sample; wherein the allele pattern of patients selected from the group consisting of p53pro/p53pro, p53arg/p53arg and p53pro/p53arg are indicative of a risk factor for developing disease associated with different polymorphic forms of wildtype p53. Notably, individuals who are p53arg/arg are at greater risk of developing pathologies associated with human papillomavirus infections, including cervical cancer.
Patent CA-2302544-A1 (CA)
Title: Method for producing air-quench toughened glass plate
Inventor: KIKUTA MASASHI
IPC: C03B27/044
Filed: 1999-07-06
Abstract: In a production process for air-quench toughened glass plates, a failed glass plate containing nickel sulfide (NiS) is removed through subjecting it to an effective forced fracture. Such forced fracture is carried out during batchwise soaking treatment after a toughening step, or in a toughening step after causing cracks to occur in an annealing step before the toughening step, or in a toughening step after causing cracks to occur in a pretreatment step before the toughening step, or during continuous annealing after a toughening step. This method can be used for producing a high quality toughened glass plate free of NiS.
Patent CA-2302908-A1 (CA)
Inventor: ILIASEVITCH STEPAN
IPC: G05F3/26
Filed: 2000-03-29
Abstract: The invention relates to a differential current mirror circuit with low or eliminated differential current offset. The circuit comprises first and second input transistors Q1i and Q2i whose physical layout is being matched and emitters connected together to a first reference voltage V ref1 through an input resistance means Ri; first and second output transistors Q1o and Q2o whose physical layout is being matched and emitters connected together to a second reference voltage V ref2 through an output resistance means R o; collector and base of the first (second) input transistor Q1i (Q2i) being connected to the base of the first (second) output transistor Q1o (Q2o) and to a first (second) input current terminal to which a first (second) input current i1i (i2i) is being supplied; and collector of the first (second) output transistor Q1o (Q2o) being connected to a first (second) output current terminal generating first (second) output current i1o (i2o). By using only one input and one output regeneration resistors and providing that the layout of the input and output transistors is matched in pairs, the output differential current offset of the circuitry is eliminated. A cascade of differential current mirror connected in series is also provided.
Patent CA-2303653-A1 (CA)
Title: A whitened coffee concentrate
Inventor: BODENSTAB STEFAN
IPC: A23F5/14
Filed: 2000-04-03
Abstract: A stable, whitened coffee concentrate which has a solids concentration above about 25% by weight. The whitened coffee concentrate is a mixture of milk solids, soluble coffee solids, and coffee aroma. The coffee aroma stabilises the concentrate. The coffee concentrate may be provided in the form of a single-serve pack.
Patent CA-2303848-A1 (CA)
Title: Substituted anilides
Inventor: HARRIS NEIL VICTOR
IPC: A61P19/02
Filed: 1998-11-02
Abstract: The invention is directed to physiologically active compounds of formula (I) wherein: R1 is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; X1, X2 and X6 independently represent N or CR10; and one of X3, X4 and X5 represents CR11 and the others independently represents N or CR10 (where R10 is hydrogen, amino, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl; and R11 represents a group -L1-Ar1-L2-Y); and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (.alpha.4.beta.1).